- Bio-Techne (TECH, Financial) launches an Early Access Program for a new spatial protein proximity detection assay.
- The assay offers high-resolution visualization of protein interactions within tissues using RNAscopeā¢ technology.
- Proof-of-concept data to be presented at the 2025 American Association for Cancer Research (AACR) annual meeting.
Bio-Techne Corporation (NASDAQ: TECH), a prominent player in the life sciences industry, has unveiled an Early Access Program for its innovative spatial protein proximity detection assay. This next-generation technology, rooted in Advanced Cell Diagnostics' RNAscopeā¢ platform, provides unprecedented high-resolution visualization of protein interactions within intact tissues, promising to extend functional insights into disease mechanisms.
This cutting-edge assay bridges a crucial gap in spatial biology by offering a clear visual representation of protein interactions while maintaining their spatial context, a feat challenging for conventional methods that often discard spatial fidelity. The technology is compatible with the RNAscopeā¢ Multiomic LS workflow on BOND RX, making it a valuable tool for researchers studying immune checkpoint dynamics, bispecific antibodies, and synaptic junction protein interactions.
The Early Access Program targets select research institutions and scientists interested in integrating spatial protein proximity capabilities into their studies. Bio-Techne plans to showcase proof-of-concept data and relevant case studies during the 2025 American Association for Cancer Research (AACR) annual meeting, underscoring the potential of this advance in oncology and broader disease research areas.
Bio-Techne Corporation (TECH, Financial) continues to lead in life sciences innovation, with its extensive product portfolio contributing to approximately $1.2 billion in net sales for fiscal 2024. The company's strategic innovations in bioactive reagents and diagnostic tools support both research and clinical diagnostics efforts worldwide.
